Cargando…
ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) comprises at least two main biologically distinct entities: germinal center B-cell (GCB) and activated B-cell (ABC) subtype. Albeit sharing common lesions, GCB and ABC DLBCL present subtype-specific oncogenic pathway perturbations. ABC DLBCL is typic...
Autores principales: | Sartori, Giulio, Napoli, Sara, Cascione, Luciano, Chung, Elaine Yee Lin, Priebe, Valdemar, Arribas, Alberto Jesus, Mensah, Afua Adjeiwaa, Dall’Angelo, Michela, Falzarano, Chiara, Barnabei, Laura, Forcato, Mattia, Rinaldi, Andrea, Bicciato, Silvio, Thome, Margot, Bertoni, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582153/ https://www.ncbi.nlm.nih.gov/pubmed/34763718 http://dx.doi.org/10.1186/s13046-021-02159-3 |
Ejemplares similares
-
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type
por: Priebe, Valdemar, et al.
Publicado: (2020) -
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma
por: Napoli, Sara, et al.
Publicado: (2021) -
Harnessing the Molecular Fingerprints of B Cell Lymphoma for Precision Therapy
por: Mensah, Afua Adjeiwaa, et al.
Publicado: (2022) -
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
por: Mensah, Afua Adjeiwaa, et al.
Publicado: (2014) -
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
por: Arribas, Alberto J., et al.
Publicado: (2022)